Matches in Wikidata for { <http://www.wikidata.org/entity/Q57824258> ?p ?o ?g. }
Showing items 1 to 46 of
46
with 100 items per page.
- Q57824258 description "artículu científicu espublizáu n'agostu de 2018" @default.
- Q57824258 description "im August 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57824258 description "scientific article published on 01 August 2018" @default.
- Q57824258 description "wetenschappelijk artikel" @default.
- Q57824258 description "наукова стаття, опублікована в серпні 2018" @default.
- Q57824258 name "Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"" @default.
- Q57824258 name "Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"" @default.
- Q57824258 type Item @default.
- Q57824258 label "Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"" @default.
- Q57824258 label "Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"" @default.
- Q57824258 prefLabel "Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"" @default.
- Q57824258 prefLabel "Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"" @default.
- Q57824258 P1433 Q57824258-D90750D8-3B08-483F-8724-641D128F694E @default.
- Q57824258 P1476 Q57824258-E2A845B2-E5F7-4B0F-800C-0DED01340455 @default.
- Q57824258 P2093 Q57824258-32EF9022-F00F-4EFD-B3E3-56457D44D5EB @default.
- Q57824258 P2093 Q57824258-89B26793-BD70-4794-AB66-8E04EC285955 @default.
- Q57824258 P2093 Q57824258-BDE2F257-90F4-4D11-A6B4-2A23C01320C2 @default.
- Q57824258 P304 Q57824258-984F9616-B22C-431E-B60F-6BB95F9F2827 @default.
- Q57824258 P31 Q57824258-3D72A6A5-3F6E-4250-AA83-69D23CE0D165 @default.
- Q57824258 P356 Q57824258-C47C05B3-0329-4E8A-88C9-E61AB4BBED5C @default.
- Q57824258 P407 Q57824258-A5D7ED7D-8130-4974-9AFD-9A6707FA92AF @default.
- Q57824258 P433 Q57824258-F87C1F30-D2BA-4704-AA07-C2805BB8607E @default.
- Q57824258 P478 Q57824258-A9BCC6E3-F4C5-4AF1-9098-E2B1E96EF6CB @default.
- Q57824258 P50 Q57824258-086BF9E7-1192-4E41-9F0D-F6E9F35E25B7 @default.
- Q57824258 P577 Q57824258-9F1F0400-B738-4A55-B888-C28292086330 @default.
- Q57824258 P698 Q57824258-91DD7834-F8E9-48DF-B56C-0755F39BCFA1 @default.
- Q57824258 P921 Q57824258-4679489c-332c-46df-9e1f-c1d52c1f5637 @default.
- Q57824258 P921 Q57824258-5C3314D3-763D-40E8-A7F8-8A9A6CF6DE53 @default.
- Q57824258 P356 CIRCULATIONAHA.118.035717 @default.
- Q57824258 P698 30354619 @default.
- Q57824258 P1433 Q578091 @default.
- Q57824258 P1476 "Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"" @default.
- Q57824258 P2093 "David R Matthews" @default.
- Q57824258 P2093 "Kenneth W Mahaffey" @default.
- Q57824258 P2093 "Vlado Perkovic" @default.
- Q57824258 P304 "660-661" @default.
- Q57824258 P31 Q13442814 @default.
- Q57824258 P356 "10.1161/CIRCULATIONAHA.118.035717" @default.
- Q57824258 P407 Q1860 @default.
- Q57824258 P433 "6" @default.
- Q57824258 P478 "138" @default.
- Q57824258 P50 Q63101609 @default.
- Q57824258 P577 "2018-08-01T00:00:00Z" @default.
- Q57824258 P698 "30354619" @default.
- Q57824258 P921 Q37525 @default.
- Q57824258 P921 Q389735 @default.